A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway

A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8(+) T cells mediate the antitumor effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagato, Toshihiro, Celis, Esteban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063146/
https://www.ncbi.nlm.nih.gov/pubmed/25050210
http://dx.doi.org/10.4161/onci.28440
_version_ 1782321755011940352
author Nagato, Toshihiro
Celis, Esteban
author_facet Nagato, Toshihiro
Celis, Esteban
author_sort Nagato, Toshihiro
collection PubMed
description A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8(+) T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.
format Online
Article
Text
id pubmed-4063146
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40631462015-05-15 A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway Nagato, Toshihiro Celis, Esteban Oncoimmunology Author's View A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8(+) T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens. Landes Bioscience 2014-05-15 /pmc/articles/PMC4063146/ /pubmed/25050210 http://dx.doi.org/10.4161/onci.28440 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Nagato, Toshihiro
Celis, Esteban
A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
title A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
title_full A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
title_fullStr A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
title_full_unstemmed A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
title_short A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
title_sort novel combinatorial cancer immunotherapy: poly-ic and blockade of the pd-1/pd-l1 pathway
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063146/
https://www.ncbi.nlm.nih.gov/pubmed/25050210
http://dx.doi.org/10.4161/onci.28440
work_keys_str_mv AT nagatotoshihiro anovelcombinatorialcancerimmunotherapypolyicandblockadeofthepd1pdl1pathway
AT celisesteban anovelcombinatorialcancerimmunotherapypolyicandblockadeofthepd1pdl1pathway
AT nagatotoshihiro novelcombinatorialcancerimmunotherapypolyicandblockadeofthepd1pdl1pathway
AT celisesteban novelcombinatorialcancerimmunotherapypolyicandblockadeofthepd1pdl1pathway

Ejemplares similares